#USA #New York #Securities Fraud #Pomerantz Law Firm #Tyra Biosciences

Investor Alert: Tyra Biosciences Under Investigation by Pomerantz Law Firm

Pomerantz LLP, a renowned law firm with a strong reputation in corporate litigation, is currently investigating claims from investors associated with Tyra Biosciences, Inc. (NASDAQ: TYRA). The investigation is focused on whether Tyra and some of its executives might have engaged in securities fraud or other unlawful business activities, which could potentially impact shareholders.

This inquiry comes on the heels of a troubling press release issued by Tyra on September 9, 2026, where they announced preliminary results from their Phase 2 clinical trial named SURF302. This study has been crucial as it evaluates the effectiveness of oral dabogratinib in patients suffering from FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). Despite the company reporting a favorable safety profile, it was highlighted that a notable proportion of study participants—14% and 9%—experienced Grade 3 treatment-emergent adverse events with the administered doses of 60 mg and 50 mg, respectively.

The announcement had a significant impact on the company's stock, leading to a dramatic decline of $4.72 per share, or 17.66%, which resulted in a closing price of $22.01 per share on the day of the announcement. Investors are understandably concerned about this sharp drop and are now seeking to understand their rights and potential remedies.

Pomerantz LLP is extending a call to all investors of Tyra Biosciences to contact attorney Danielle Peyton for further details about their investigation. The firm, which has its headquarters in New York and additional offices in Chicago, Los Angeles, London, Paris, and Tel Aviv, has a long history of advocating for the rights of investors and has secured numerous multimillion-dollar verdicts in favor of class members in various securities fraud cases. Pomerantz's founder, Abraham L. Pomerantz, is often referred to as the dean of the class action bar, having pioneered the practice of filing securities class action lawsuits, and the firm maintains this commitment to fight for investors' rights.

As Tyra navigates the fallout from this press release and the ensuing investor concerns, the firm's investigation will look closely at the company's disclosures, executive communications, and adherence to securities regulations. Investors who believe they may have been affected by Tyra's actions are encouraged to reach out to Pomerantz to possibly participate in a class action lawsuit that may arise from these events.

This situation serves as a stark reminder of the risks associated with investing in biotechnology firms, particularly those navigating the complex landscape of clinical trials. Investors are advised to stay informed and consider their legal options, especially in light of such significant stock movements following company announcements.

For more information on how to join the investigations or to discuss your situation, you can contact Danielle Peyton via email at [email protected] or call 646-581-9980, extension 7980.

As news develops, stakeholders will be watching closely to understand the full impact of these recent events on Tyra Biosciences and its operations going forward.